Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma

Gregory A. Wiseman*, Christine A. White, Michael Stabin, William L. Dunn, William Erwin, Magnus Dahlbom, Andrew Raubitschek, Kastytis Karvelis, Timothy Schultheiss, Thomas E. Witzig, Richard Belanger, Stewart Spies, Daniel H.S. Silverman, Judy R. Berlfein, Eric Ding, Antonio J. Grillo-López

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

217 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I/II <sup>90</sup>Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma'. Together they form a unique fingerprint.

Medicine & Life Sciences